Talecris Biotherapeutics’ aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency, was granted orphan drug designation by the FDA. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, particularly emphysema. Currently, there are no approved, inhaled treatments available to treat AAT deficiency. Orphan drug designation is granted to encourage the development of treatments that prevent, di...